The Chicago Entrepreneur

Hims & Hers Health says it will offer compounded GLP-1 drugs, despite FDA warnings

Hims & Hers Health’s stock jumped more than 30% Monday morning after the health and wellness platform said it would offer compounded versions of popular GLP-1 drugs.

Previous post Grayscale CEO Michael Sonnenshein steps down as firm’s bitcoin ETF bleeds assets
Next post As hurricane season arrives, these stocks could present opportunities